Concurrent lung and liver ablation proves feasible

Article

Interventional radiologists in Italy have shown the feasibility of concurrent radio-frequency ablation of hepatic and pulmonary tumors.

Interventional radiologists in Italy have shown the feasibility of concurrent radio-frequency ablation of hepatic and pulmonary tumors.

Dr. Davide Becanni and colleagues at the University of Florence performed 65 RF ablations in 25 patients with hepatic and pulmonary metastases from colorectal carcinoma. Both hepatic and pulmonary lesions were treated in a single-session procedure using one RF generator with either single or cluster probes. RFA successfully ablated all lesions, as confirmed by either CT or PET follow-up.

No liver complications were reported, although five patients who were treated for pulmonary metastases developed pneumothorax.

Physicians still have to define the best target population and the cost-benefit ratio for dual RFA. But his study shows that the procedure can reduce hospitalization time without adding to the complication rate, Becanni said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.